Adam Fein, President of Pembroke Consulting, Inc.


Adam J. Fein, Ph.D., is the president of Pembroke Consulting, Inc., a management advisory and business research firm based in Philadelphia. He also is the CEO of Pembroke’s Drug Channels Institute, a leading management educator for and about the pharmaceutical industry.

Dr. Fein is one of the country’s foremost experts on pharmaceutical economics and the drug distribution system. Top manufacturers call on Dr. Fein’s insights and judgment, to create successful commercial strategies and make better strategic decisions in our evolving healthcare environment.

Dr. Fein’s popular and influential Drug Channels blog is the go-to source for definitive and comprehensive industry analysis, delivered with a witty edge. He has published hundreds of academic and industry articles, and is regularly quoted in such national publications as The Wall Street JournalThe New York TimesForbes, and many others.

Dr. Fein also is a popular speaker. He inspires his audiences to think strategically with content-rich and entertaining keynote presentations.

Dr. Fein earned his doctoral degree from the Wharton School of Business at the University of Pennsylvania and a B.A., summa cum laude, from Brandeis University. He lives in Philadelphia with his wife and their two children.

Joel Freedman, Chairman of Paladin Healthcare Capital and Management

Joel Freedman (002).jpg

Joel Freedman is majority shareholder and Chairman of Paladin Healthcare Capital, which invests in, lends to, and acquires underperforming health care companies; and Paladin Healthcare Management, which manages several community hospitals, including Howard University Hospital in Washington, DC. He also serves as President and Co-Founder of Avanti Hospitals, which owns and operates four hospitals in South and East Los Angeles. Before establishing Avanti, he served as Managing Partner of Paladin Capital and co-founded CompWest Insurance Company. In his role as Chairman of Paladin, Mr. Freedman has been the principal architect of Paladin’s recently announced acquisition of Philadelphia-based Hahnemann University Hospital, St. Christopher’s Hospital for Children, several affiliated physician practices, and all related real property.  Hahnemann and St. Christopher’s serve as the primary teaching hospitals for The Drexel University College of Medicine and have rich histories of providing quality care to the greater Philadelphia area. Mr. Freedman is a founding member of the Healthcare Policy Advisory Council at Harvard Medical School, current Chairman of the Industry Work Group for Harvard’s Healthcare Markets and Regulation Lab, and serves on the Board of the Leonard D. Schaeffer Center for Health Policy and Economics at the University of Southern California.

Mike Doyle, President at QPID Health, an eviCore company

Michael J Doyle PHOTO 9-28-17.png

Mr. Doyle has a distinguished track record providing business value. Under his leadership, QPID Health, a spin out of Massachusetts General Hospital, was established as a commercial software company, then became part of eviCore healthcare, the leader in medical benefits management.

Prior to QPID, Mr. Doyle was CEO and Chairman of Medsphere Systems, which pioneered an open-source electronic health record. Previously, he held leadership positions in a variety of healthcare and technology enterprises. 

Mr. Doyle is a Fellow in the American College of Healthcare Executives (FACHE). He holds a BS in Biology from Tufts University, and an MBA in hospital administration from the University of Chicago, where he was a Kaiser Fellow.


Ted Smith, CEO of Revon Systems


Ted joined Revon Systems as Chief Executive Officer in 2016. Ted's prior position was Chief Innovation Officer for the City of Louisville, KY. In that capacity, he created the largest real-time asthma monitoring project in conjunction with the Robert Wood Johnson Foundation and Propeller Health. Ted was also an early member of the Office of the National Coordinator (ONC) of Health IT as the US Department of Health and Human Services where he focussed on the DC-to-VC and Health Datapalooza programs. Ted co-founded MedTrackAlert in 2007 which was acquired by Remedy Health in 2009. Ted was the general manager of CNET's B2B brands and was a founding board member of NASA's National Space Biomedical Research Institute Industry Board. Ted holds a bachelor's degree in biology and psychology from Allegheny College and an MA and PhD in cognitive neuroscience from Miami University (Ohio). Ted's completed his post-doctoral studies at MIT. Ted was co-investigator for the Neurolab space shuttle mission in 1998

Joy Bauer, MS, RDN, Nutrition and Health Expert for NBC's TODAY Show


Joy Bauer is a registered dietitian and one of the country’s leading health authorities. Best known as the nutrition expert for NBC’s TODAY show, Joy is also the author of 12 best-selling books and a monthly columnist for Woman’s Day magazine. She is the founder of Nourish Snacks (a delicious line of healthy goodies) and the official nutritionist for the New York City Ballet. Passionate about delivering scientifically sound, realistic information to millions of Americans, Joy has received countless awards, including the National Media Excellence Award from two of the most esteemed organizations, the Academy of Nutrition and Dietetics and the American Society of Nutrition Science.

This coming March, Joy is thrilled to be debuting her own weekly TV show on NBC, where she’ll feature the latest in wellness and dish out mouthwatering recipes to help people live happier and healthier lives. 


Brian G. Murphy, General Partner at NewSpring Health Capital

Brian Murphy.jpg

Mr. Murphy is a General Partner of NewSpring Health Capital, General Partner of NewSpring Ventures, and a Partner of NewSpring Capital, with more than 25 years of corporate management and development experience, focused primarily in healthcare services.  He has a strong background in business strategy, investment structuring, organizational growth, and negotiation of mergers and acquisitions.  Prior to NewSpring, he founded Acquisition Management Services, Inc. (AMS), a diversified corporate development advisory firm focusing on middle market companies.  AMS closed more than 330 acquisitions for its buy side clients.  He has also founded two venture-backed startups, WordWave, a legal court reporting and broadcast captioning leader (later sold to Merrill Corp.) and Precyse Solutions, a provider of medical transcription and health information services to acute care hospitals.  Previously, he held executive positions for several healthcare service companies, most notably NovaCare, Inc., Heritage Health Systems, and Partners National Health Plans.  He is currently a board member of ContinuumRx Services, SUN Behavioral Health, Verisma Systems and Seniorlink.  He is also a member of the Foundation Board of SUNY Cortland.  He received a B.S. in science from the State University of New York at Cortland.

Troy Mullane, Principal at The Boston Consulting Group

Troy Mullane.jpg

Troy Mullane, Principal, joined The Boston Consulting Group in 2011 as an Associate. He has worked in cases across health care services, biopharma, retail, and consumer goods. His work has focused on helping our clients in a number of areas, with a focus on large-scale organizational change and sales force effectiveness. Through his work, he has helped clients to better harness digital tools and the data they have available to better serve patients in a variety of therapeutic areas.

Troy holds a BS in Business Administration from the University of North Carolina, where he concentrated in International Business.


Curtis Duggan, CEO and Co-Founder of Blue Mesa Health


Curtis Duggan is the CEO and Co-Founder of Blue Mesa Health. Coming from a background as an agency owner in the field of technology, mobile product development, and user experience design, Curtis is now tackling one of the world’s most pressing health problems: the burden posed by lifestyle-related and chronic disease.

While co-founding and running Dactyl Studios, his British Columbia-based mobile app agency, for four years, Curtis saw firsthand how profoundly the mobile and cloud revolutions were transforming various industries in the early 2010s. However, he observed that the health care industry in particular was not leveraging advances in technology and experience design with the same velocity as other industries. In 2015, he decided to dedicate his life to addressing the global chronic disease burden by partnering with co-founders and investors to co-create Blue Mesa Health, a digital health company with a mission to provide chronic disease prevention solutions in the USA and internationally.

Blue Mesa Health delivers Transform and Transformemos, English- and Spanish-language digital translations of the CDC’s landmark preventive program, the Diabetes Prevention Program.


Mansur Shomali, MD, CM, Medical Director, WellDoc, Inc. and Endocrinology Faculty Member, MedStar Union Memorial Hospital

Dr. Mansur Shomali.jpg

Mansur E. Shomali, MD, CM, has served as medical director for the diabetes technology company WellDoc since 2012, where he oversees many of the clinical aspects of the company’s diabetes products. While at WellDoc, Dr. Shomali’s responsibilities have included directing product development and innovation, supporting the quality systems and regulatory strategies, directing research and data science activities, and presenting to payers as well as external stakeholders.  He also actively takes care of patients with diabetes, obesity, and other endocrine and metabolic conditions at MedStar Union Memorial Hospital in Baltimore, Maryland, where he sees patients two days per week. Dr. Shomali also maintains an academic affiliation at the University of Maryland School of Medicine where he has the rank of clinical associate professor and has served as instructor of medicine at The Johns Hopkins University School of Medicine, where he enjoys teaching medical students and physicians-in-training.

Dr. Shomali completed an undergraduate degree in biomedical engineering at The Johns Hopkins University. He received his medical degree from McGill University in Montreal, Canada and completed an internship and a residency in internal medicine at the University of Maryland School of Medicine. Subsequently he completed fellowships in endocrinology and metabolism at Massachusetts General Hospital and Harvard Medical School in Boston, Massachusetts. He is certified by the American Board of Internal Medicine in endocrinology, diabetes, and metabolism.

Dr. Shomali has a research interest in novel ways to treat individuals with type 2 diabetes. He has served as principle investigator for numerous clinical trials of novel pharmacologic agents as well as investigator-initiated studies examining the improvement of care for individuals with diabetes. His expertise is in complex pharmacologic approaches and in the use of technology in healthcare. He has published over 30 peer-reviewed medical articles and textbook chapters, has served on several journal editorial boards, and has given hundreds of scientific and educational presentations. Currently Dr. Shomali is an active member of the American Association of Clinical Endocrinology and the American Diabetes Association.

Piotr Gorecki, MD, FACS, Chief of Laparoscopy and Medical Director of Bariatric and Metabolic Surgery Center at New York Methodist Hospital

Dr. Piotr Gorecki.jpg

Piotr Gorecki, M.D., F.A.C.S., F.A.S.M.B.S is a board-certified surgeon and a Director of Bariatric and Metabolic Surgery Center at the New York-Presbyterian Brooklyn Methodist Hospital. He also is an Associate Professor of Clinical Surgery at Weill Medical College of Cornell University. Dr. Gorecki completed a special fellowship in advanced laparoscopic surgery at the Mayo Clinic. His training included a variety of innovative and advanced laparoscopic surgical techniques. Dr. Gorecki has been involved in the development of new laparoscopic techniques and in teaching them to other surgeons. His clinical and research interest has been focused on minimally invasive treatment of morbid obesity, metabolic syndrome and diabetes. He was one of the first surgeons in the region to utilize these techniques and has some of the largest experience in the country in doing so.

For more information, please visit

See Dr. Gorecki's CV for more information about his background.  

Dr. Robert Cook-Deegan, Founding Director of IGSP's Center for Genome Ethics, Law & Policy

BCD passport size IGSP.JPG

Robert Cook-Deegan is professor, School for the Future of Innovation in Society, and Consortium for Science, Policy & Outcomes at Arizona State University. He founded and directed Duke’s Center for Genome Ethics, Law & Policy 2002- 2012, and Duke-in-Washington through June 2016.  Before Duke: National Academies of Science, Engineering and Medicine 1991-2002; National Center for Human Genome Research (NIH) 1989-1990; and congressional Office of Technology Assessment 1982-1988. MD, University of Colorado,1979; and BA in chemistry (magna cum laude), Harvard, 1975.  Author of The Gene Wars: Science, Politics, and the Human Genome and over 250 other publications.

Dr. James Wilson, Director of Penn's Orphan Disease Center


James M. Wilson, MD, PhD, is the Director of the Orphan Disease Center at the University of Pennsylvania. Dr. Wilson began his work in gene therapy during his graduate studies at the University of Michigan over 30 years ago. He created the first and largest academic-based program in gene therapy after being recruited to Penn in 1993. He initially focused on the clinical translation of existing gene transfer technologies but soon redirected his efforts to the development of second and third generation gene transfer platforms; the first of which was licensed to a biotechnology company he founded that resulted in the first, and only, commercially approved gene therapy in the western hemisphere.  He is currently leading a national dialogue on the challenges of commercializing these potentially lifesaving treatments due to the disruptive nature they will have on traditional business models. Dr. Wilson was noted by the journal Nature Biotechnology to be the “second most productive bio-entrepreneur in life sciences.”


Adam Hanina, CEO and Co-Founder of AICure

Adam Hanina (1) (1).jpg

Adam Hanina is co-founder and CEO of AiCure, a venture and NIH-funded company that has developed artificial intelligence to confirm medication ingestion by clinical trial participants and high-risk patients in real time. Mr. Hanina has been responsible for much of the vision and strategy at AiCure and is the primary inventor of over 20 patents. He is a passionate advocate for the use of healthcare software as a population health tool and has directed much of his previous work to this end. Prior to AiCure, Mr. Hanina contributed to the development of Cerner Corporation’s European strategy and was a Visiting Fellow of eHealth at Imperial College in London, UK. He has acted as a subject-matter expert on patient monitoring technologies for the National Institutes of Health (NIH). He holds an MBA from the Wharton School of Business.

Eran Ofir, CEO and Co-Founder of Somatix, Inc.

Eran bio 1.JPG

Eran Ofir is the CEO and Co-Founder of Somatix, a big-data analytics software company in the digital health domain, offering solutions based on analysis of data derived from wearable devices.

Eran has over twenty years of executive roles in multinational companies, where he established and led business units at AOL Mobile, Amdocs, Convergys and NCR. Eran lived and worked in Israel, South Africa, China and the US, selling software, hardware and services to customers in telecom, internet, retail, utilities, financial services and healthcare sectors. Tel-Aviv University graduate in Electrical Engineering (BSc) and Finance-Marketing MBA.

Dr. Rachel Haurwitz, CEO and President of Caribou Biosciences

Haurwitz headshot.jpg

Rachel is a co-founder of Caribou Biosciences and has been President and CEO since its inception. She has a research background in CRISPR-Cas biology, and is also a co-founder of Intellia Therapeutics. In 2014, she was named by Forbes Magazine to the "30 Under 30" list in Science and Healthcare, and in 2016, Fortune Magazine named her to the "40 Under 40" list of the most influential young people in business. Rachel is an inventor on several patents and patent applications covering multiple CRISPR-derived technologies, and she has co-authored scientific papers in high impact journals characterizing CRISPR-Cas systems. Rachel earned an A.B. in Biological Sciences from Harvard College, and received a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.

Nicole Paraggio, Senior Manager at Accenture


Nicole Paraggio is a Senior Manager in Accenture’s Life Sciences Strategy practice. She has worked at fifteen life sciences clients during her almost ten year tenure at Accenture focusing most recently on digital disruption and applications of digital across the pharmaceutical value chain. In doing so she has established a unique ability to apply digital health across functional domains from Clinical to Medical to Commercial Sales & Marketing. Digital technologies that Nicole has worked with her clients to embed into their digital agendas include: augmented reality, internet of things, connected health devices, advanced analytics, and machine learning.


Prior to Accenture, Nicole received an M.S. from Duke University in Pathology where her thesis focused on vaccine immunology. Nicole also has a B.S. in both Physics and Cell & Molecular Biology from Tulane University.